Zyn could soon be allowed to tell adult smokers, in plain language, that switching to its pouches lowers their risk of serious smoking-related disease. At a January 2026 FDA advisory meeting, the agency itself said the evidence behind that claim appears “scientifically accurate” — a potential turning point for how nicotine pouches are marketed in the US.
What happened
On January 22, 2026, the FDA’s Tobacco Products Scientific Advisory Committee (TPSAC) reviewed a Modified Risk Tobacco Product (MRTP) application from Swedish Match USA, a Philip Morris International subsidiary, covering 20 Zyn pouch products in 3-mg and 6-mg strengths. The lineup includes Zyn Chill, Cool Mint, Citrus, Coffee, Menthol, Peppermint, Smooth, Spearmint, Wintergreen and Cinnamon.
PMI is asking the FDA for permission to state that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” In its own presentation to the committee, the FDA said: “The evidence suggests the proposed modified risk claim is scientifically accurate.” These are the same Zyn products that already cleared the FDA’s premarket review back in January 2025.
Why it matters
This would be a first-of-its-kind authorization. Zyn already dominates the US nicotine pouch market — roughly two-thirds of it, with about $3.24 billion in sales by one Goldman Sachs analysis — but it has never been allowed to make reduced-risk claims in its advertising. An MRTP green light would let it speak directly to adult smokers about switching, reshaping how the fastest-growing nicotine category is sold. The FDA also noted that youth nicotine pouch use remains relatively low and that the proposed claim did not increase young adults’ intention to use Zyn.
What this means for US nicotine users
For adults who already use pouches or are weighing a switch from cigarettes, this signals where the regulatory winds are blowing: toward recognizing smoke-free products as a distinct, lower-risk lane. It does not mean pouches are risk-free — they still deliver nicotine and remain strictly for adults 21+. But if the claim is authorized, expect clearer, FDA-sanctioned messaging about relative risk and likely more attention on pouches as a category.
“Smoke-free products, like Zyn, play a critical role… and provide adults who smoke with important information to guide their choices and a real opportunity to change,” said Keagan Lenihan, chief external affairs officer for PMI US.
The bottom line
The FDA has not issued a final decision and has set no deadline, so nothing changes on shelves today. But an advisory review in which the agency itself calls the lower-risk claim “scientifically accurate” is a notable milestone for the pouch category. We’ll keep tracking it — if the MRTP is granted, it’ll be one of the biggest shifts in nicotine marketing in years.
